Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials

OBJECTIVE: We examined the efficacy and safety of galcanezumab after treatment cessation in randomized double‐blind, placebo‐controlled, migraine prevention studies (EVOLVE‐1; EVOLVE‐2). BACKGROUND: Galcanezumab is indicated for migraine prevention in adults. METHODS: Adults with episodic migraine w...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauffer, Virginia L., Wang, Shufang, Voulgaropoulos, Menelaos, Skljarevski, Vladimir, Kovacik, Amy, Aurora, Sheena K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593785/
https://www.ncbi.nlm.nih.gov/pubmed/30942898
http://dx.doi.org/10.1111/head.13508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593785/
https://www.ncbi.nlm.nih.gov/pubmed/30942898
http://dx.doi.org/10.1111/head.13508

Ejemplares similares